PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.8% - What's Next?

PDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) traded down 5.8% during trading on Friday . The stock traded as low as $1.42 and last traded at $1.46. 261,041 shares were traded during mid-day trading, an increase of 18% from the average session volume of 221,346 shares. The stock had previously closed at $1.55.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PDSB. HC Wainwright restated a "buy" rating and set a $21.00 price target on shares of PDS Biotechnology in a research note on Wednesday, December 18th. B. Riley cut their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Monday, November 25th. Finally, StockNews.com downgraded shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, November 9th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, PDS Biotechnology has an average rating of "Moderate Buy" and an average price target of $11.67.

PDS Biotechnology Trading Down 2.8 %

The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The company's 50 day moving average price is $1.69 and its two-hundred day moving average price is $2.60. The firm has a market cap of $52.75 million, a PE ratio of -1.22 and a beta of 1.88.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company's stock valued at $1,586,000 after acquiring an additional 37,142 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in PDS Biotechnology during the 2nd quarter worth approximately $146,000. Squarepoint Ops LLC acquired a new position in PDS Biotechnology during the 2nd quarter valued at approximately $120,000. Vontobel Holding Ltd. lifted its stake in shares of PDS Biotechnology by 233.3% during the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company's stock worth $153,000 after buying an additional 28,000 shares during the period. Finally, XTX Topco Ltd grew its holdings in shares of PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company's stock valued at $257,000 after buying an additional 47,528 shares during the last quarter. Hedge funds and other institutional investors own 26.84% of the company's stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.